Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

• DOI: 10.1200/jco.20.00522
• Publication Date: 2020-08-17T19:59:26Z
• Authors: Filip Janku; Albiruni R. Abdul...; Ping Chi; Michael C. Heinrich; Margaret von Mehren; Robin L. Jones; Kristen Ganjoo; Jonathan Trent; Hans Gelderblom; Neeta Somaiah; Simin Hu; Oliver Rosen; Ying Su; Rodrigo Ruiz-Soto; Michael Gordon; Suzanne George
• Keywords: PDGFRA; Imatinib Mesylate

In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib a novel switch-control kinase inhibitor designed to inhibit wide range